YERVOY

OTTAWA, Canada, February 2026 — Canada’s Drug Agency (CDA-AMC) has issued a conditional reimbursement recommendation for Opdivo® (nivolumab) plus...

MONTREAL, Dec. 17, 2025 — Bristol Myers Squibb Canada announced that Canada’s Drug Agency (CDA-AMC) has issued a positive...